Tag: EpCAM

A Method to Obtain CTCs from Murine Colorectal Cancer Model

– Circulating Tumor Cells, or CTCs, are the cancer cells that stem from the primary tumor and enter the blood circulation. Most CTCs can survive in the bloodstream without attaching to the surface; therefore, we can detect them directly from the blood of most cancer patients. CTCs in the blood…

Continue Reading A Method to Obtain CTCs from Murine Colorectal Cancer Model

Anti-EpCAM (Extracellular region) Antibody | Scientist.com

Anti-EpCAM (Extracellular region) Antibody | Scientist.com Skip to Main Content Go to Main Navigation Form: Protein G Purified Gene: EPCAM Host: Mouse Rrid: AB_3068418 Type: Primary Antibody Clone: M039 Buffer: PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol Target: EpCAM (Extracellular region) Isotype: IgG1 Storage: Storage at -20°C…

Continue Reading Anti-EpCAM (Extracellular region) Antibody | Scientist.com

Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids

Human tissue samples Tissue samples and annotated data were obtained, and experimental procedures were performed within the framework of the non-profit foundation HTCR, including informed patient consent. Intestinal organoid and tumouroid cell culture Supplementary Table 1 provides anonymized basic donor information. After isolation of intestinal crypts following a previously described…

Continue Reading Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids

CAR-T Cell Immunotherapies For Cancer Market Analysis 2024: Business Share And Size Forecast By Regions Till 2031

(MENAFN– The Express Wire) The Global “CAR-T Cell Immunotherapies for Cancer Market ” Growth Forecast Report 20242031 is an essential tool for understanding the growth strategies, and various segments of industry by Type [ CD19, BCMA, EPCAM ] and Applications [ Hematological Cancer, Solid Tumor, Other Oncological Disorders ]. The…

Continue Reading CAR-T Cell Immunotherapies For Cancer Market Analysis 2024: Business Share And Size Forecast By Regions Till 2031

Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2

Objective: The aim of this study is to evaluate an AAV vector that can selectively target breast cancer cells and to investigate its specificity and anti-tumor effects on breast cancer cells both in vitro and in vivo, offering a new therapeutic approach for the treatment of EpCAM-positive breast cancer. Methods:…

Continue Reading Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2

EpCAM (VU1D9) Mouse mAb | Cell Signaling Technology

Limited Uses Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer’s terms and conditions that are in addition to, or different from, those contained herein, unless separately…

Continue Reading EpCAM (VU1D9) Mouse mAb | Cell Signaling Technology

EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.

EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. Publication ,  Journal Article Wang, T; Gantier, MP; Xiang, D; Bean, AG; Bruce, M; Zhou, S-F; Khasraw, M; Ward, A; Wang, L; Wei, MQ; AlShamaileh, H; Chen, L; She, X … Published in: Theranostics Understanding the…

Continue Reading EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.

PE Anti-EpCAM antibody [VU-1D9] (ab112068)

Mouse Monoclonal EPCAM antibody – conjugated to PE. Validated in Flow Cyt and tested in Human samples. Cited in 17 publications. Alternative names= EGP, ESA, KSA, gp4, AUA1, EGP2, Ly74, M1S2, M4S1, MK 1, 17 1A, CD326, CO17A, DIAR5, EGP 2, EGP40, EPCAM, KS1/4, M1S 1, MIC18, TACD1, TROP1, 323/A3,…

Continue Reading PE Anti-EpCAM antibody [VU-1D9] (ab112068)

APC Anti-EpCAM antibody [EPR20532-225] (ab237398)

Rabbit Recombinant Monoclonal EPCAM antibody – conjugated to APC. Validated in Flow Cyt and tested in Human samples. Alternative names= EGP, ESA, KSA, gp4, AUA1, EGP2, Ly74, M1S2, M4S1, MK 1, 17 1A, CD326, CO17A, DIAR5, EGP 2, EGP40, EPCAM, KS1/4, M1S 1, MIC18, TACD1, TROP1, 323/A3, EGP314, Ep CAM,…

Continue Reading APC Anti-EpCAM antibody [EPR20532-225] (ab237398)

EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors

The efficacy of CAR-T cells for solid tumors is unsatisfactory. EpCAM is a biomarker of epithelial tumors, but the clinical feasibility of CAR-T therapy targeting EpCAM is lacking. Here, we report pre- and clinical investigations of EpCAM-CAR-T cells for solid tumors. We demonstrated that EpCAM-CAR-T cells costimulated by Dectin-1 exhibited…

Continue Reading EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors

EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma

The objective of this study was to evaluate a composite biomarker of EpCAM-positive circulating tumor cells and serum AFP to identify patients at high risk of early recurrence within 2 years after liver resection. While AFP is elevated in less than half of patients with HCC, it is associated with tumor…

Continue Reading EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma

Elevated stress response marks deeply quiescent reserve cells of gastric chief cells

Generation of inducible H2b-GFP knock-in mice Generation of inducible H2b-GFP knock-in mice was performed by using CRISPR/Cas943. In brief, a mixture containing a sgRosa26-1 crRNA43 (8.7 ng/μl, Fasmac, Japan), a tracrRNA (14.3 ng/μl, Fasmac, Japan), a single strand oligo donor nucleotide (ssODN) composed of 5′ arm, adenovirus splicing acceptor, SV40 pA, TRE3G…

Continue Reading Elevated stress response marks deeply quiescent reserve cells of gastric chief cells

11-100test | EpCAM antibody [VU-1D9] (PerCP-Cy5.5) Clinisciences

Application Note *Optimal dilutions/concentrations should be determined by the researcher. Application Recommended Dilution FACS 4 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension Not tested in other applications. Calculated MW 35 kDa. ( Note ) Product Note This antibody recognizes an epitope within EGF-like…

Continue Reading 11-100test | EpCAM antibody [VU-1D9] (PerCP-Cy5.5) Clinisciences

APC anti-human CD326 EpCAM Antibody anti-CD326

Description CD326 is also known as EpCAM, tumor associated calcium signal transducer 1, epithelial cell surface antigen, epithelial glycoprotein 2, EGP2, adenocarcinoma associated antigen, and TROP1. CD326 is a type I transmembrane protein containing six disulfide bridges and one THYRO domain. This cell surface glycosylated 40 kD protein is highly…

Continue Reading APC anti-human CD326 EpCAM Antibody anti-CD326

AB-F1181UC-25 | FITC Anti-Mouse CD326 Antibody[G8.8] Clinisciences

Product Name Sizes Price FITC Anti-Mouse CD326/EpCAM Antibody[G8.8] 50Tests, 100Tests, 100Tests×2 Check More PE Anti-Mouse CD326/EpCAM Antibody[G8.8] 50Tests, 100Tests, 100Tests×2 Check More APC Anti-Mouse CD326/EpCAM Antibody[G8.8] 50Tests, 100Tests, 100Tests×2 Check More PE/Cyanine7 Anti-Mouse CD326/EpCAM Antibody[G8.8] 50Tests, 100Tests, 100Tests×2 Check More Elab Fluor® 488 Anti-Mouse CD326/EpCAM Antibody[G8.8] 50Tests, 100Tests, 100Tests×2 Check More PE Anti-Mouse CD326/EpCAM Antibody[G8.8] 25μg, 100μg Check More APC Anti-Mouse…

Continue Reading AB-F1181UC-25 | FITC Anti-Mouse CD326 Antibody[G8.8] Clinisciences

H5223-100ug | Human EpCAM / TROP1 Protein, His Tag Quimigen

Shark attack: high affinity binding proteins derived from shark vNAR domains by stepwise in vitro affinity maturation Authors: S Zielonka, et al. Journal: J Biotechnol 2014 Application: Library Screening by FACS Request for Full-text Production of bispecific antibodies in “Knobs-into-Holes” using a cell-free expression system. Authors: Xu Y, et al….

Continue Reading H5223-100ug | Human EpCAM / TROP1 Protein, His Tag Quimigen

Anti-Epithelial Cell Adhesion Molecule (EpCAM) Antibody, clone 8

Anti-Epithelial Cell Adhesion Molecule (EpCAM) Antibody, clone 8 | Merck Life Science Philippines The store will not work correctly when cookies are disabled. JavaScript seems to be disabled in your browser. For the best experience on our site, be sure…

Continue Reading Anti-Epithelial Cell Adhesion Molecule (EpCAM) Antibody, clone 8

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla, Inc. Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be presented at upcoming IASLC conference in early December and discussed at KOL event on December 4, 2023 Observed new PRs with…

Continue Reading BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

CytomX Therapeutics Reports Third Quarter 2023 Financial

– CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 – – CX-2051 (EpCAM-directed ADC) comprehensive preclinical profile presented at 14th Annual World ADC Conference; IND filing on track for year-end – – Updated CX-801 (conditionally activated interferon alpha-2b) preclinical data presented at…

Continue Reading CytomX Therapeutics Reports Third Quarter 2023 Financial

BioAtla to Participate in the Jefferies London Healthcare Conference

BioAtla, Inc. SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled…

Continue Reading BioAtla to Participate in the Jefferies London Healthcare Conference

Recombinant Full Length Rat Epithelial Cell Adhesion Molecule(Epcam) Protein, His-Tagged RFL3774RF

Source : E.coli expression system Species : Rattus norvegicus (Rat) Tag : His Form : Lyophilized powder Protein length : Full Length of Mature Protein (24-315) AA Sequence…

Continue Reading Recombinant Full Length Rat Epithelial Cell Adhesion Molecule(Epcam) Protein, His-Tagged RFL3774RF

Preparation and in vitro Activity of Anti-EpCAM Immunotoxin

     Preparation and in vitro Activity of Anti-EpCAM Immunotoxin LIU Yu-ping1,DENG Chang-ping2,MA Xing-yuan2,LIU Qiu-li1,BAO Wen1,ZHENG Wen-yun1,**() 1 Shanghai Key Laboratory…

Continue Reading Preparation and in vitro Activity of Anti-EpCAM Immunotoxin

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

CytomX Therapeutics Inc. – IND filing for CX-801 anticipated by the end of 2023 – SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that preclinical data supporting CX-801, its conditionally activated…

Continue Reading CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

APC Anti-EpCAM antibody [VU-1D9] (ab239288)

Mouse Monoclonal EPCAM antibody – conjugated to APC. Validated in Flow Cyt and tested in Human samples. Alternative names= EGP, ESA, KSA, gp4, AUA1, EGP2, Ly74, M1S2, M4S1, MK 1, 17 1A, CD326, CO17A, DIAR5, EGP 2, EGP40, EPCAM, KS1/4, M1S 1, MIC18, TACD1, TROP1, 323/A3, EGP314, Ep CAM, Ep-CAM,…

Continue Reading APC Anti-EpCAM antibody [VU-1D9] (ab239288)

Researchers identify biology behind aggressive breast cancers in Black women

Establishment of PROCR+/ZEB1+/PDGFRα+ (PZP) cell lines from the Normal-Healthy breast tissues of women of African ancestry. a Genetic ancestry mapping of breast tissue donors (KTB40, KTB42, KTB32, KTB53, KTB57, and KTB59) using a panel of 41-SNP. b PROCR+/EpCAM‒ cells are enriched in established cell lines from women of African ancestry…

Continue Reading Researchers identify biology behind aggressive breast cancers in Black women

EpCAM, a broadly expressed, validated cancer target rescued by novel antibody technologies | Antibodies

EpCAM, a broadly expressed, validated cancer target rescued by novel antibody technologies Details Category: Antibodies Published on Tuesday, 24 October 2023 11:51 Hits: 242 BARCELONA, Spain I October 24, 2023 I La Merie Publishing released its newest product reviewing the pipeline of anti-EpCAM antibody therapy candidates in R&D: EpCAM-Targeted…

Continue Reading EpCAM, a broadly expressed, validated cancer target rescued by novel antibody technologies | Antibodies

For Those With Lynch Syndrome, Exercise May Be A Useful Defense Against Colorectal Cancer

Amanda Brink, DNP, APRN, FNP-BC, AOCNP Colorectal cancer (CRC) currently ranks as the fourth most commonly diagnosed cancer and the second leading cause of cancer-related deaths in the United States.1 While most CRCs cases arise sporadically, between 5 and 10% of cases are attributed to hereditary cancer syndromes.2 Lynch syndrome,…

Continue Reading For Those With Lynch Syndrome, Exercise May Be A Useful Defense Against Colorectal Cancer

Recombinant Full Length Human Epithelial Cell Adhesion Molecule(Epcam) Protein, His-Tagged RFL5563HF

Source : E.coli expression system Species : Homo sapiens (Human) Tag : His Form : Lyophilized powder Protein length : Full Length of Mature Protein (24-314) AA Sequence…

Continue Reading Recombinant Full Length Human Epithelial Cell Adhesion Molecule(Epcam) Protein, His-Tagged RFL5563HF

CytomX Therapeutics Presents Preclinical Profile of

– CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload – – Preclinical data demonstrate a favorable predicted therapeutic index and efficacy across multiple EpCAM-expressing tumors, including colorectal cancer (CRC) – – CX-2051 IND filing expected by year-end 2023…

Continue Reading CytomX Therapeutics Presents Preclinical Profile of

Recombinant Rhesus monkey EpCAM protein (His tag) (ab226418)

Recombinant Rhesus monkey EpCAM protein (His tag) is a HEK 293 Fragment protein 24 to 265 aa range, >95% purity, < 1 EU/µg endotoxin level and validated in SDS-PAGE. Alternative names= EGP, ESA, KSA, gp4, AUA1, EGP2, Ly74, M1S2, M4S1, MK 1, 17 1A, CD326, CO17A, DIAR5, EGP 2, EGP40,…

Continue Reading Recombinant Rhesus monkey EpCAM protein (His tag) (ab226418)

Purified anti-human CD326 (EpCAM) Antibody, CD326, W18060B

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.   *These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog…

Continue Reading Purified anti-human CD326 (EpCAM) Antibody, CD326, W18060B

Biotin Anti-EpCAM antibody [EPR677(2)] (ab199758)

Rabbit Recombinant Monoclonal EPCAM antibody – conjugated to Biotin. Validated in IHC-P and tested in Human samples. Alternative names= EGP, ESA, KSA, gp4, AUA1, EGP2, Ly74, M1S2, M4S1, MK 1, 17 1A, CD326, CO17A, DIAR5, EGP 2, EGP40, EPCAM, KS1/4, M1S 1, MIC18, TACD1, TROP1, 323/A3, EGP314, Ep CAM, Ep-CAM,…

Continue Reading Biotin Anti-EpCAM antibody [EPR677(2)] (ab199758)

An Intrabody against B-Cell Receptor-Associated Protein 31 (BAP31) Suppresses the Glycosylation of the Epithelial Cell-Adhesion Molecule (EpCAM) via Affecting the Formation of the Sec61-Translocon-Associated Protein (TRAP) Complex

. 2023 Sep 30;24(19):14787. doi: 10.3390/ijms241914787. Affiliations Expand Affiliation 1 College of Life Science and Health, Northeastern University, 195 Chuangxin Road, Hunnan District, Shenyang 110819, China. Item in Clipboard Tianyi Wang et al. Int J Mol Sci. 2023. Show details Display options Display options Format AbstractPubMedPMID . 2023 Sep 30;24(19):14787. doi:…

Continue Reading An Intrabody against B-Cell Receptor-Associated Protein 31 (BAP31) Suppresses the Glycosylation of the Epithelial Cell-Adhesion Molecule (EpCAM) via Affecting the Formation of the Sec61-Translocon-Associated Protein (TRAP) Complex

Anti-EpCAM antibody [AUA1] (AB308057) | Abcam

Mouse Recombinant Monoclonal EPCAM antibody. Validated in IHC-P, WB, ICC/IF, Flow Cyt and tested in Human samples. Alternative names= EGP, ESA, KSA, gp4, AUA1, EGP2, Ly74, M1S2, M4S1, MK 1, 17 1A, CD326, CO17A, DIAR5, EGP 2, EGP40, EPCAM, KS1/4, M1S 1, MIC18, TACD1, TROP1, 323/A3, EGP314, Ep CAM, Ep-CAM,…

Continue Reading Anti-EpCAM antibody [AUA1] (AB308057) | Abcam

EOGT enables residual Notch signaling in mouse intestinal cells lacking POFUT1

Single cell RNAseq bioinformatics Bioinformatic trajectory analysis of scRNAseq data obtained from Epcam+CD45− C57Bl6/J adult intestinal crypt cells and deposited as GSE188339 was performed as described35. Primers and antibodies Primer sequences are given in Supplementary Table 1 and antibodies are given in Supplementary Table 2. Generation of Chinese hamster ovary…

Continue Reading EOGT enables residual Notch signaling in mouse intestinal cells lacking POFUT1

FDA Grants Marketing Authorization to First DNA Test to Assess Genetic Predisposition to Select Cancers

The FDA has granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test designed to detect genetic variants associated with an elevated risk of developing certain types of cancer.1 Additionally, the panel could also help identify potential cancer-associated variants in patients who have…

Continue Reading FDA Grants Marketing Authorization to First DNA Test to Assess Genetic Predisposition to Select Cancers

FDA Clears Test That Detects Hereditary Gene Variants Linked to Certain Cancers

The Food and Drug Administration (FDA) has cleared the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test that assesses an individual’s predisposition for certain cancers.  Designed for heritable germline mutations, the test analyzes 47 genes known to be associated with elevated risk for developing breast, ovarian, uterine, prostate,…

Continue Reading FDA Clears Test That Detects Hereditary Gene Variants Linked to Certain Cancers

Invitae’s First of Its Kind Cancer Test Receives FDA Marketing Authorization

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those are just two genes of many known genetic drivers of cancer. The FDA has granted marketing authorization to an Invitae test…

Continue Reading Invitae’s First of Its Kind Cancer Test Receives FDA Marketing Authorization

First Blood Test for Dozens of Hereditary Cancers Approved by FDA

Credit: Nadasaki / Getty Images The FDA has approved the first blood test that can help identify hundreds of potentially cancer-associated hereditary variants. The Invitae Common Hereditary Cancers Panel evaluates a blood sample to identify DNA variants in 47 genes associated with an elevated risk of developing certain types of…

Continue Reading First Blood Test for Dozens of Hereditary Cancers Approved by FDA

FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types

For Immediate Release: September 29, 2023 Today, the U.S. Food and Drug Administration granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test that can help detect hundreds of genetic variants associated with an elevated risk of developing certain cancers. The test can…

Continue Reading FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types

Human EPCAM knockout A-431 cell lysate (AB261708)

EPCAM KO cell lysate available now. KO validated by Immunocytochemistry, Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9 X = 2 bp deletion Frameshift: 99.58%. Alternative names= 17 1A, 323/A3, AUA1, Adenocarcinoma-associated antigen, Antigen identified by monoclonal antibody AUA1, CD326, CD326 antigen,…

Continue Reading Human EPCAM knockout A-431 cell lysate (AB261708)

Recombinant Human EpCAM protein (ab151338)

Recombinant Human EpCAM protein is a HEK 293 Fragment protein 24 to 265 aa range, >95% purity, < 1 EU/µg endotoxin level and validated in SDS-PAGE, HPLC. Alternative names= EGP, ESA, KSA, gp4, AUA1, EGP2, Ly74, M1S2, M4S1, MK 1, 17 1A, CD326, CO17A, DIAR5, EGP 2, EGP40, EPCAM, KS1/4,…

Continue Reading Recombinant Human EpCAM protein (ab151338)

Clinical significance of stem cell biomarkers epcam, lgr5 and lgr4 mrna levels in lymph nodes of colon cancer patients

@article{84db1f17-26c0-4aa8-a4d6-34bbb57031cc, abstract = {{<p>The significance of cancer stem cells (CSCs) in initiation and progression of colon cancer (CC) has been established. In this study, we investigated the utility of measuring mRNA expression levels of CSC markers EpCAM, LGR5 and LGR4 for predicting survival outcome in surgically treated CC patients. Expression…

Continue Reading Clinical significance of stem cell biomarkers epcam, lgr5 and lgr4 mrna levels in lymph nodes of colon cancer patients

Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc,  (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection…

Continue Reading Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

Focusing on the development of BsAbs in China, YZY Biopharma Announces Proposed Listing on the Main Board of SEHK

HONG KONG, Sept 13, 2023 – (ACN Newswire) – – Wuhan YZY Biopharma Co., Ltd. (“YZY Biopharma” or the “Company”, together with its subsidiaries, the “Group”, stock code: 2496.HK), a biotechnology company dedicated to developing bispecific antibody (BsAb)-based therapies to treat cancer-associated complications, cancer and age-related ophthalmologic diseases, announced the…

Continue Reading Focusing on the development of BsAbs in China, YZY Biopharma Announces Proposed Listing on the Main Board of SEHK

Electrochemical immunosensor based on titanium dioxide grafted MXene for EpCAM antigen detection

. 2023 Aug 16;652(Pt A):549-556. doi: 10.1016/j.jcis.2023.08.099. Online ahead of print. Affiliations Expand Affiliations 1 Department of Applied Chemistry, Delhi Technological University, Delhi 110042, India. Electronic address: 29.sweetyjain@gmail.com. 2 Department of Applied Chemistry, Delhi Technological University, Delhi 110042, India. Electronic address: dkumar@dce.ac.in. Item in Clipboard Sweety et al. J Colloid Interface…

Continue Reading Electrochemical immunosensor based on titanium dioxide grafted MXene for EpCAM antigen detection

“Selection and enumeration of low EpCAM expressing breast cancer CTCs u” by Brandy Charon Snowden

Abstract Breast cancer cells overexpress EpCAM that can be used as a marker to select breast cancer CTCs from heterogeneous clinical samples, even when present in low abundance. This study used MDA-MB-231 cells which have a low expression level of EpCAM (1.7 x 103 binding sites per cell.3) Herein, we…

Continue Reading “Selection and enumeration of low EpCAM expressing breast cancer CTCs u” by Brandy Charon Snowden

Potent and selective eradication of tumor cells by an EpCAM-targeted Ras-degrading enzyme.

Subject All institutes and research themes of the Radboud University Medical Center; Radboudumc 19: Nanomedicine RIMLS: Radboud Institute for Molecular Life Sciences Abstract Despite decades of efforts, an urgent need remains to develop tumor cell-selective rat sarcoma (Ras)-targeting therapies that can treat patients with Ras-driven tumors. Here we report modular…

Continue Reading Potent and selective eradication of tumor cells by an EpCAM-targeted Ras-degrading enzyme.

Quantitative whole-tissue 3D imaging reveals bacteria in close association with mouse jejunum mucosa

Mice All animal husbandry and experiments were approved by the Caltech Institutional Animal Care and Use Committee (IACUC, protocol #1646). The EED mouse model was established following the previously published protocol9 with slight adaptations. On day 1 of the experiment, just-weaned, specific pathogen-free (SPF) C57BL/6 J male mice were received from…

Continue Reading Quantitative whole-tissue 3D imaging reveals bacteria in close association with mouse jejunum mucosa

CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in September. H.C. Wainwright 25 th Annual Global Investment Conference Date: Tuesday, September 12,…

Continue Reading CytomX Therapeutics to Present at Upcoming September Investor Conferences

Adecatumumab (Anti-EpCAM / TROP1 / CD326) | CD markers antibody

Catalog No.A2512 Synonyms: MT 201; Anti-Human EPCAM Recombinant Antibody For research use only.Not for use in humans. Adecatumumab (Anti-EpCAM / TROP1 / CD326) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of…

Continue Reading Adecatumumab (Anti-EpCAM / TROP1 / CD326) | CD markers antibody

What type of word is ‘epcam’? Epcam can be

Unfortunately, with the current database that runs this site, I don’t have data about which senses of ~term~ are used most commonly. I’ve got ideas about how to fix this but will need to find a source of “sense” frequencies. Hopefully there’s enough info above to help you understand the…

Continue Reading What type of word is ‘epcam’? Epcam can be

Preclinical evaluation of EpCAM-binding designed ankyrin repeat proteins (DARPins) as targeting moieties for bimodal near-infrared fluorescence and photoacoustic imaging of cancer

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi.org/10.3322/caac.21660. Article  PubMed  Google Scholar  Khan MA, Hakeem AR, Scott N, Saunders RN. Significance…

Continue Reading Preclinical evaluation of EpCAM-binding designed ankyrin repeat proteins (DARPins) as targeting moieties for bimodal near-infrared fluorescence and photoacoustic imaging of cancer

Anti-Mouse EpCAM (CD326) In Vivo Antibody

Epithelial cell adhesion molecule (EpCAM; also known as CD326 or Tacstd1) is a 40 kDa type I transmembrane glycoprotein composed of an extracellular domain, single transmembrane domain, and the intracellular domain Ep1CD1. EpCAM functions in cell adhesion, signaling, differentiation, migration, proliferation, formation and maintenance of organ morphology, and morphogenic movements…

Continue Reading Anti-Mouse EpCAM (CD326) In Vivo Antibody

Transient naive reprogramming corrects hiPS cells functionally and epigenetically

Cell culture All cell lines used and derived by different approaches in this study are listed in Supplementary Table 1. Detailed information about the experimental design, materials and reagents is presented in the Reporting Summary. Primary human adult dermal fibroblasts (HDFa) from three different female donors were obtained from Gibco…

Continue Reading Transient naive reprogramming corrects hiPS cells functionally and epigenetically

Ex vivo expansion of lung cancer-derived disseminated cancer cells from lymph nodes identifies cells associated with metastatic progression

doi: 10.1002/ijc.34658. Online ahead of print. Steffi Treitschke  1 , Kathrin Weidele  1 , Adithi Ravikumar Varadarajan  1 , Giancarlo Feliciello  1 , Jens Warfsmann  1 , Sybille Vorbeck  1 , Bernhard Polzer  1 , Catherine Botteron  1 , Martin Hoffmann  1 , Vadim Dechand  1 , Tobias Mederer  2 , Florian Weber  1   3 , Melanie Werner-Klein  2 , Tobias Robold …

Continue Reading Ex vivo expansion of lung cancer-derived disseminated cancer cells from lymph nodes identifies cells associated with metastatic progression

Diagnostics | Free Full-Text | Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Salivary Gland Cancer: Correlation with the Biological Behavior

1. Introduction Salivary gland neoplasms comprise a diverse group of tumors with different biological behaviors and clinical outcomes. The incidence of malignant neoplasms of the salivary glands varies among different researchers, with an estimated incidence of 0.4–2.6:100,000. They account for 3–6% of head and neck malignancies and less than 1%…

Continue Reading Diagnostics | Free Full-Text | Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Salivary Gland Cancer: Correlation with the Biological Behavior

Dysregulated cross-talk between alveolar epithelial cells and stromal cells in idiopathic pulmonary fibrosis reduces epithelial regenerative capacity

In idiopathic pulmonary fibrosis (IPF) constant epithelial micro-injury and aberrant interactions within the stromal micro-environment lead to abnormal alveolar repair and fibrosis. We hypothesized that alveolar epithelial regenerative responses in IPF are impaired due to disturbed crosstalk between epithelial cells and their stromal niche. We established organoid cultures from unfractionated…

Continue Reading Dysregulated cross-talk between alveolar epithelial cells and stromal cells in idiopathic pulmonary fibrosis reduces epithelial regenerative capacity

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

CytomX Therapeutics Inc. – CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 – – IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) anticipated in the fourth quarter of 2023 – – Management to hold conference call today at 5 p.m. EDT / 2…

Continue Reading CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

CytomX Therapeutics Reports Second Quarter 2023 Financial

– CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 –                         – IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) anticipated in the fourth quarter of 2023 – – Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT –…

Continue Reading CytomX Therapeutics Reports Second Quarter 2023 Financial

ELISA Kit for Epithelial Cell Adhesion Molecule (EPCAM) | SEB283Hu

CD326; TACSTD1; EGP; KSA; M4S1; MIC18; TROP1; HEGP2; ESA; Epithelial glycoprotein; Adenocarcinoma-associated antigen; Tumor Associated Calcium Signal Transducer 1 Product No.SEB283Hu Organism SpeciesHomo sapiens (Human) Same name, Different species. Sample TypeSerum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids Test MethodDouble-antibody Sandwich…

Continue Reading ELISA Kit for Epithelial Cell Adhesion Molecule (EPCAM) | SEB283Hu

Early-onset tufting enteropathy in HAI-2-deficient mice is independent of matriptase-mediated cleavage of EpCAM

doi: 10.1242/dev.201801. Online ahead of print. Affiliations Expand Affiliations 1 Proteases and Tissue Remodeling Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA. 2 Section of Oncopathology and Regenerative Biology, Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki 8891692, Japan. Item…

Continue Reading Early-onset tufting enteropathy in HAI-2-deficient mice is independent of matriptase-mediated cleavage of EpCAM

Recombinant Rat Epcam protein, hFc-tagged Epcam-7481R

Home / Products / Recombinant Proteins / Recombinant Rat Epcam protein, hFc-tagged Recombinant Rat Epcam protein, hFc-tagged Online Inquiry Epcam Related Products By Species By Source By Tag Price Inquiry Welcome! For price inquiries, please feel free to contact us through the…

Continue Reading Recombinant Rat Epcam protein, hFc-tagged Epcam-7481R

BioAtla Reports Second Quarter 2023 Financial Results and

Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug Administration (FDA) meeting request for potentially registrational study of BA3011 in non-small cell lung cancer (NSCLC) study; FDA feedback and initiation of study…

Continue Reading BioAtla Reports Second Quarter 2023 Financial Results and

Evolutionary histories of breast cancer and related clones

Data reporting No statistical methods were used to determine the sample size. The experiments were not randomized. Pathologists were blinded to the genetic alterations in each sample during histopathological evaluation. Participants and materials We enroled 207 female patients with breast cancer who underwent surgery at the Kyoto University Hospital and…

Continue Reading Evolutionary histories of breast cancer and related clones

BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023

BioAtla, Inc. SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday,…

Continue Reading BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023

RARRES2 regulates lipid metabolic reprogramming to mediate the development of brain metastasis in triple negative breast cancer | Military Medical Research

Tumor samples from patients Biopsies of primary breast tumors and breast tumors that had metastasized to the brain were obtained from patients with TNBC at the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital of the Chinese Academy of Medical Sciences and Peking Union Medical College. Single-cell RNA sequencing…

Continue Reading RARRES2 regulates lipid metabolic reprogramming to mediate the development of brain metastasis in triple negative breast cancer | Military Medical Research

Plasticity of circulating tumor cells in small cell lung cancer

Liquid biopsy samples Patients with histological or cytological confirmation of chemotherapy-naive SCLC were recruited and consented at The Christie NHS Foundation Trust according to an ethically approved protocol (NHS Northwest 9 Research Ethical Committee). Informed written consent was obtained from all subjects. Experimental protocols were approved by the Institutional Review board of…

Continue Reading Plasticity of circulating tumor cells in small cell lung cancer

CytomX Therapeutics Announces New Employment Inducement Grants

CytomX Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., July 20, 2023 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that on July 19, 2023, the Company granted its recently appointed Senior Vice President, Chief Medical Officer, Yu-Waye (Wayne) Chu,…

Continue Reading CytomX Therapeutics Announces New Employment Inducement Grants

Human EpCAM Matched Antibody Pair Set [ABP-S-021194]

Human EpCAM antibody pair set for sandwich ELISA useCapture Antibody: Monoclonal IgGDetection Antibody: Unconjugated-Rabbit Monoclonal IgG (Note: Please select the requirements to fit you project. If you have any other requirements, please specify. If no specific requirements, you don’t need to select any button.) For Research Use Only. AgonistAgonist AntagonistAntagonist…

Continue Reading Human EpCAM Matched Antibody Pair Set [ABP-S-021194]

Cancers | Free Full-Text | A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer

1. Introduction Typically, tumors in patients with ovarian cancer (OC) are often diagnosed at an advanced stage [1]. Currently, cytoreductive therapy with platinum-based chemotherapy is the mainstay of disease management, to which the majority of patients with OC initially respond. Unfortunately, 70% of these patients eventually develop refractory recurrences [2]….

Continue Reading Cancers | Free Full-Text | A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer

Evidence for EpCAM and Cytokeratin Expressing Epithelial Cells in Normal Human and Murine Blood and Bone Marrow

This paper presents a reproducible method with new findings on the presence of epithelial cells in normal human and mouse blood and bone marrow using flow cytometry and immunofluorescence microscopy. Krt1-14;mTmG transgenic mice were used as an in vivo method to confirm these findings. This technique demonstrates a reproducible method…

Continue Reading Evidence for EpCAM and Cytokeratin Expressing Epithelial Cells in Normal Human and Murine Blood and Bone Marrow

Recombinant Human CD25 – IL-2RA (CHO)

Product Type SelectAntibody (536)Biologically Active (52)Capture Antibody (26)Cytokine (6)Detection Antibody (26)Dual ELISpot Set (9)Dual Fluorospot Set (9)ELISA Kit (111)ELISA Set (36)ELISpot Kit (22)ELISpot Pairs (20)ELISpot Set (20)Isotype Control (17)Recombinant Antibody (12)Recombinant Protein (19)SARS-CoV-2 (11)SARSCoV2 (8) Analyte SelectADAM-10 (1)Angiopoietin-2 (3)BCMA (2)BIOTIN (1)c-Myc (1)CD10 (4)CD102 (1)CD102 / ICAM-2 (4)CD105 (5)CD106 (2)CD106 /…

Continue Reading Recombinant Human CD25 – IL-2RA (CHO)

LOINC 85449-7 Social enviromental domain risk level [ePCAM]

Term Description The risk level is calculated as the four question response total (out of a possible 400) [LOINC: 85448-9] divided by 400, then multiplied by 100 to express the risk as a percent. The ePCAM guidance recommends “Routine Care” for a risk level of 0-25%, “Active Monitoring” for 26-50%,…

Continue Reading LOINC 85449-7 Social enviromental domain risk level [ePCAM]

New test might expand ability to find tumor cells in blood

A new blood test that can quantify tumor cells circulating in the bloodstream is ready for testing in the clinic. In preliminary work, the test has been shown to produce results comparable to the only similar test currently approved by the U.S. Food and Drug Administration, researchers in Seattle report. Both…

Continue Reading New test might expand ability to find tumor cells in blood

Biotin Mouse Anti-Human CD326 (EpCAM)

The 9C4 monoclonal antibody specifically binds to human epithelial cell adhesion molecule (EpCAM), also known as adenocarcinoma associated antigen and CD326. EpCAM is an approximately 40-kDa type 1 transmembrane glycoprotein and adhesion molecule that mediates intercellular interactions via homotypic adhesion. The epithelial cells present in non-squamous epithelia and tumors derived…

Continue Reading Biotin Mouse Anti-Human CD326 (EpCAM)

CRISPR/Cas13a-Based MicroRNA Detection in Tumor-Derived Extracellular Vesicles

doi: 10.1002/advs.202301766. Online ahead of print. Affiliations Expand Affiliations 1 Center for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA. 2 Cancer Center, Massachusetts General Hospital, Boston, MA, 02114, USA. 3 Department of Radiology, Massachusetts General Hospital, Boston, MA, 02114, USA. Item in Clipboard Jae-Sang Hong et al. Adv Sci…

Continue Reading CRISPR/Cas13a-Based MicroRNA Detection in Tumor-Derived Extracellular Vesicles

FITC anti-human CD326 EpCAM Antibody anti-CD326

Description CD326 is also known as Ep-CAM, tumor associated calcium signal transducer 1, epithelial cell surface antigen, epithelial glycoprotein 2, EGP2, adenocarcinoma associated antigen, and TROP1. CD326 is a type I transmembrane protein containing six disulfide bridges and one THYRO domain. This cell surface glycosylated 40 kD protein is highly…

Continue Reading FITC anti-human CD326 EpCAM Antibody anti-CD326

How do tumor exosomes communicate cancer progression?

Exosomes are extracellular vesicles ranging between 30 and 150 nm in diameter that are released from different kinds of cells, including tumor cells. They have the potential to induce apoptosis, modulate the immune system, and work as biomarkers for diagnosis. As a key component of cell-to-cell communication, exosomes can control the…

Continue Reading How do tumor exosomes communicate cancer progression?

Prioritization and functional validation of target genes from single-cell transcriptomics studies

List of congruent tip TEC markers The list of congruent tip TEC markers was extracted from a publicly available lung tumor study8. In brief, to identify congruent tip cell markers across freshly isolated human and murine TECs, as well as cultured human TECs, all genes that were most highly expressed…

Continue Reading Prioritization and functional validation of target genes from single-cell transcriptomics studies

Associations Between Clinical Factors and Skin Neoplasms in Longitudinal Observational Cohort of Individuals with LS

The following is a summary of “Clinical factors associated with skin neoplasms in individuals with Lynch syndrome in a longitudinal observational cohort,” published in the JUNE 2023 issue of Dermatology by Zhong, et al. For a study, researchers sought to identify clinical factors associated with developing skin neoplasms in individuals…

Continue Reading Associations Between Clinical Factors and Skin Neoplasms in Longitudinal Observational Cohort of Individuals with LS

JCM | Free Full-Text | Reduction of EpCAM-Positive Cells from a Cell Salvage Product Is Achieved by Leucocyte Depletion Filters Alone

1. Introduction Allogeneic blood transfusion is potentially life-saving for bleeding patients, but it is not totally risk-free [1]. Intraoperative cell salvage, also known as autotransfusion, is a strategy designed to reduce the need for allogeneic transfusions. This procedure involves the collection of patient blood from the surgical field, which is…

Continue Reading JCM | Free Full-Text | Reduction of EpCAM-Positive Cells from a Cell Salvage Product Is Achieved by Leucocyte Depletion Filters Alone

Combination of CEACAM5, EpCAM and CK19 gene expressions in mediastinal lymph node micrometastasis is a prognostic factor for non-small cell lung cancer | Journal of Cardiothoracic Surgery

Patients From July 2013 through July 2014, 32 consecutive patients with operable NSCLC, according to NCCN guidelines stage 2B and/or lower, and with no prior neoadjuvant treatment regimens were enrolled in the study. Before the operation, every patient underwent a positron emission tomography (PET) scan and brain magnetic resonance imaging…

Continue Reading Combination of CEACAM5, EpCAM and CK19 gene expressions in mediastinal lymph node micrometastasis is a prognostic factor for non-small cell lung cancer | Journal of Cardiothoracic Surgery

ITabMed announces the IND approval from NMPA for A-337, a CD3-activating bispecific antibody targeting EpCAM to treat solid tumors | News

SHANGHAI–(BUSINESS WIRE)–Jun 7, 2023– ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3-activating bi-specific antibody targeting EpCAM. This is a “Phase I, Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of A-337 in patients with…

Continue Reading ITabMed announces the IND approval from NMPA for A-337, a CD3-activating bispecific antibody targeting EpCAM to treat solid tumors | News

Lipid nanoparticles-based therapy in liver metastasis

Key Points Liver metastasis, which is highly prevalent in advanced malignancies, was associated with poor prognosis. Contemporary therapies in liver metastasis were associated with the lack of metastatic-targeting ability, significant systemic toxicities and incapability of tumor microenvironment (TME) modulations. Lipid nanoparticles (LNP)-based strategies would overcome the deficiencies of conventional approaches…

Continue Reading Lipid nanoparticles-based therapy in liver metastasis

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

CytomX Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Healthcare Conference on Thursday, June 8…

Continue Reading CytomX Therapeutics to Present at the Jefferies Healthcare Conference

BV421 Mouse Anti-Human CD326 (EpCAM)

The 9C4 monoclonal antibody specifically binds to human epithelial cell adhesion molecule (EpCAM), also known as adenocarcinoma associated antigen and CD326. EpCAM is an approximately 40-kDa type 1 transmembrane glycoprotein and adhesion molecule that mediates intercellular interactions via homotypic adhesion. The epithelial cells present in non-squamous epithelia and tumors derived…

Continue Reading BV421 Mouse Anti-Human CD326 (EpCAM)

Cancers | Free Full-Text | mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth

Author Contributions Conceptualization, L.W., W.B. and V.G.; methodology, Y.H., J.S. (John Sienkiewicz), J.S. (Jinying Sun), H.Z., H.H., S.X., R.B. and L.H.; software, Y.H., J.S. (John Sienkiewicz) and J.S. (Jinying Sun); validation, H.Z. and J.S. (John Sienkiewicz); formal analysis, V.G.; investigation, V.G. and L.W.; resources, L.W.; data curation, Y.H., J.S. (John…

Continue Reading Cancers | Free Full-Text | mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth

Ras-induced EpCAM and several other membrane proteins.

A. Microarray data (GSE12777) for 51 breast cancer cell line was analyzed using Gene-E software. E-cadherin correlated 121 genes are enriched in first step followed by EpCAM close (correlated). These genes are presented in normal and Ras-transduced cells (right panel). B-C. Two independent microarray data sets from MCF10A and Ras-transduced…

Continue Reading Ras-induced EpCAM and several other membrane proteins.

Cytosolic EpCAM cooperates with H-Ras to regulate epithelial to mesenchymal transition through ZEB1

. 2023 May 16;18(5):e0285707. doi: 10.1371/journal.pone.0285707. eCollection 2023. Affiliations Expand Affiliations 1 Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona, United States of America. 2 Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, United States of America. Item in Clipboard Fatma A Omar et al….

Continue Reading Cytosolic EpCAM cooperates with H-Ras to regulate epithelial to mesenchymal transition through ZEB1

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla, Inc. Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in 2H23 On track for submitting a meeting request to the Food & Drug Administration (FDA) for the potentially registrational BA3011 Phase 2, part…

Continue Reading BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla Reports First Quarter 2023 Financial Results and

Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in 2H23 On track for submitting a meeting request to the Food & Drug Administration (FDA) for the potentially registrational BA3011 Phase 2, part 2 non-small…

Continue Reading BioAtla Reports First Quarter 2023 Financial Results and

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

CytomX Therapeutics Inc. – Continued progress in Phase 1 dose escalation for CX-904 (EGFRxCD3) – – IND enabling activities on track for filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 – – Bristol Myers Squibb advances Anti-CTLA-4 non-fucosylated Probody®, BMS-986288, from Phase 1…

Continue Reading CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

EpCAM tumor specificity and proteoform patterns in urothelial cancer

Background: The role of the epithelial cell adhesion molecule (EpCAM) in cancer is still unclear. EpCAM cleavage through regulated intramembrane proteolysis results in fragments which interact with both oncogenic and tumor suppressive pathways. Additionally, the EpCAM molecule itself is used as a descriptive therapeutic target in urothelial cancer (UC), while…

Continue Reading EpCAM tumor specificity and proteoform patterns in urothelial cancer

Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight, NDA Approvals, and Emerging Therapies| Key Companies- Novartis, Janssen Pharmaceuticals, and Others

PRESS RELEASE Published May 5, 2023 The “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in the Chimeric Antigen Receptor T-Cell Therapy pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including Chimeric Antigen Receptor…

Continue Reading Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight, NDA Approvals, and Emerging Therapies| Key Companies- Novartis, Janssen Pharmaceuticals, and Others

BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023

BioAtla, Inc. SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday,…

Continue Reading BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023

Feasibility study of expressing epcam + /vimentin + CTC in prostate cancer diagnosis

doi: 10.1007/s00432-023-04819-7. Online ahead of print. Affiliations Expand Affiliations 1 Department of Urology, Zhuhai People’s Hospital (Zhuhai Hospital Affiliated with Jinan University), 79 Kangning Rd., Zhuhai, 519000, China. 2 Department of Pathology, Zhuhai People’s Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai, 519000, China. 3 Department of Urology, Zhuhai People’s…

Continue Reading Feasibility study of expressing epcam + /vimentin + CTC in prostate cancer diagnosis